OncoMatch/Clinical Trials/NCT06982300
SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC
Is NCT06982300 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies non-drug interventions for nasopharyngeal carcinoma (npc).
This is an investigator-initiated, single-center clinical trial designed to evaluate the feasibility of \[68Ga\]Ga-DOTA-TOC positron emission tomography (PET) scan in patients with Epstein-Barr virus (EBV) related nasopharyngeal carcinome (NPC) prior to and three weeks after the start of induction chemotherapy or concurrent chemoradiotherapy (CRT). Archival tumor tissue from the diagnostic biopsy will be used to perform somatostatin receptor 2 (SSTR2) immunohistochemistry (IHC). Blood samples will be drawn at baseline, after three weeks, after completion of induction chemotherapy if applicable, and after CRT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IB, II, III, IVA
Prior therapy
Cannot have received: chemotherapy
Previous treatment with chemotherapy or radiotherapy for NPC
Cannot have received: radiation therapy
Previous treatment with chemotherapy or radiotherapy for NPC
Cannot have received: investigational agent
Treatment with any investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to [68Ga]Ga-DOTA-TOC injection
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify